Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levacetylleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylleucine SCHEMBL49287 | 1.00 | ALDH1A1 (0.79) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Acetylleucine SCHEMBL27683922 | 1.00 | ALDH1A1 (0.79) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL6863674 | 0.89 | ALDH1A1 (0.85) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Acetylleucine SCHEMBL282371 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL714003 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL282372 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL9438432 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL18954336 | 0.87 | ALDH1A1 (0.96) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL7923132 | 0.87 | ALDH1A1 (0.96) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL5527234 | 0.87 | ALDH1A1 (0.96) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200230128-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-23 | — | — | US | claimed |
| US-10179109-B2 | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates | CHARLESTON LABORATORIES, INC. (US) | 2019-01-15 | — | — | US | claimed |
| EP-3423041-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2019-01-09 | — | — | EP | claimed |
| US-20180344728-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-12-06 | — | — | US | claimed |
| WO-2018191584-A1 | NUTRITIONAL AND THERAPEUTIC SUPPLEMENT COMPOSITIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-18 | — | — | WO | claimed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | claimed |
| US-20170252302-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-09-07 | — | — | US | claimed |
| CN-107072961-A | Pharmaceutical composition | 查尔斯顿实验室公司 | 2017-08-18 | — | — | CN | claimed |
| EP-3191093-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| US-20170173037-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-06-22 | — | — | US | claimed |
| WO-2016040358-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2015157738-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-20140308349-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2014-10-16 | — | — | US | claimed |
| US-20140030322-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2014-01-30 | — | — | US | claimed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |